Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.
Key Topics Include:
- Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
- Describe how CMS will determine fair market prices for Medicare Part D drugs
- Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
Presenters
Director, Client Engagement
Global Market Access
ICON
Mark McCoy has over 25 years of experience in oncology, new product development, and product launches. He has developed market access and reimbursement strategies for oncology drugs in hematology, solid tumor, and rare cancers.
Divisional Principal
Market Access
ICON
Earlene Biggs has over 20 years of experience delivering insights and strategies optimizing access and stakeholder engagement for pharmaceutical and biotech companies across the product lifecycle. In the past 5 years she has led her teams to successfully deliver 200+ research and analytics engagements with ICON clients.
Head of Business Intelligence
Commercial Solutions
ICON
Bruce Capobianco has supported business technology for over 20 years. He is a thought partner and trusted business advisor to clinical and commercial businesses by contributing to innovative and efficient study designs through robust evidence generation. Bruce is an evangelist in developing and driving adoption to AI to accelerate research.
VP, Scientific Affairs
Oncology Medical Strategy
ICON
Dr. Tanja Obradovic brings more than 25 years of experience in pharmaceutical development in oncology. As strategy lead, she led immunotherapy development and life cycle management across tumor types, including melanoma, lung, women’s cancers, and other indications.
VP, PMAC Consulting
Patient Insight, Market Access and Commercial
ICON
Ki Park leads a team of principal SMEs with expertise in advanced analytics in the areas of payer, patient, promotional effectiveness, and commercial strategy. His 15 years at Symphony Health has focused on healthcare claims informatics specializing in payer and patient analytics.
Senior Principal
Global Health Economics and Outcomes Research
ICON
Nancy Risebrough is a Senior Principal within Global Health Economics and Outcomes Research at ICON. She has more than 20 years of experience working in decision analytic-modeling, health technology assessment (HTA), burden of illness studies, and reimbursement strategy and HTA submissions. Areas of therapeutic expertise include oncology, COPD, asthma, diabetes, and blood disorders.
Production Partner
ICON
Our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life.
Additional Content From ICON
Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults
Watch this webinar on addressing early onset cancer through strategic trial design, targeted launch indications, and increased trial access to speed up the delivery of impactful treatments.
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
This webinar delves into the dynamic landscape of COAs, examining their historical use and significance, current uses and best practices, and making a case for greater standardization in their implementation.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Related Content
Beyond Accelerated Approvals: External Control Arms
Hear this panel's discussion on the strategic use of external control arms and, if done correctly, how they can help bring products to market in a shorter time and for lower costs.